| Item | Current | Prior | YoY % |
|---|---|---|---|
| Net Sales | ¥6.22B | ¥6.31B | -1.4% |
| Cost of Sales | ¥5.00B | ¥5.20B | -3.8% |
| Gross Profit | ¥1.22B | ¥1.11B | +9.8% |
| SG&A Expenses | ¥1.15B | ¥1.23B | -5.9% |
| Operating Income | ¥71M | ¥-110M | +164.5% |
| Non-operating Income | ¥46M | ¥12M | +299.5% |
| Non-operating Expenses | ¥35M | ¥57M | -39.8% |
| Ordinary Income | ¥83M | ¥-156M | +153.2% |
| Profit Before Tax | ¥57M | ¥-195M | +129.0% |
| Income Tax Expense | ¥46M | ¥-10M | +560.6% |
| Net Income | ¥11M | ¥-185M | +105.8% |
| Net Income Attributable to Owners | ¥29M | ¥-182M | +115.9% |
| Total Comprehensive Income | ¥19M | ¥-200M | +109.5% |
| Depreciation & Amortization | ¥51M | ¥64M | -20.2% |
| Interest Expense | ¥26M | ¥18M | +43.4% |
| Basic EPS | ¥1.77 | ¥-10.97 | +116.1% |
| Dividend Per Share | ¥0.00 | ¥0.00 | - |
| Item | Current End | Prior End | Change |
|---|---|---|---|
| Current Assets | ¥6.79B | ¥6.70B | +¥90M |
| Cash and Deposits | ¥2.21B | ¥2.56B | ¥-343M |
| Accounts Receivable | ¥996M | ¥1.20B | ¥-199M |
| Inventories | ¥1.77B | ¥1.35B | +¥418M |
| Non-current Assets | ¥2.85B | ¥2.89B | ¥-35M |
| Item | Current | Prior | Change |
|---|---|---|---|
| Operating Cash Flow | ¥-569M | ¥-421M | ¥-148M |
| Investing Cash Flow | ¥-36M | ¥-175M | +¥139M |
| Financing Cash Flow | ¥261M | ¥379M | ¥-118M |
| Free Cash Flow | ¥-605M | - | - |
| Item | Value |
|---|---|
| Net Profit Margin | 0.5% |
| Gross Profit Margin | 19.7% |
| Current Ratio | 192.2% |
| Quick Ratio | 142.2% |
| Debt-to-Equity Ratio | 0.98x |
| Interest Coverage Ratio | 2.68x |
| EBITDA Margin | 2.0% |
| Effective Tax Rate | 81.0% |
| Item | YoY Change |
|---|---|
| Net Sales YoY Change | -1.4% |
| Item | Value |
|---|---|
| Shares Outstanding (incl. Treasury) | 17.00M shares |
| Treasury Stock | 346K shares |
| Average Shares Outstanding | 16.65M shares |
| Book Value Per Share | ¥291.84 |
| EBITDA | ¥122M |
| Item | Amount |
|---|---|
| Q2 Dividend | ¥0.00 |
| Year-End Dividend | ¥0.00 |
| Segment | Revenue | Operating Income |
|---|---|---|
| DrugDiscoverySupport | ¥938M | ¥-75M |
| InvestmentsAndConsulting | ¥5.29B | ¥245M |
| Item | Forecast |
|---|---|
| Net Sales Forecast | ¥13.50B |
| Operating Income Forecast | ¥150M |
| Ordinary Income Forecast | ¥90M |
| Net Income Attributable to Owners Forecast | ¥40M |
| Basic EPS Forecast | ¥2.40 |
| Dividend Per Share Forecast | ¥0.00 |
| Property, Plant & Equipment | ¥2.04B | ¥2.06B | ¥-18M |
| Intangible Assets | ¥535M | ¥554M | ¥-19M |
| Goodwill | ¥508M | ¥532M | ¥-24M |
| Investment Securities | ¥107M | ¥108M | ¥-808,000 |
| Total Assets | ¥9.64B | ¥9.59B | +¥56M |
| Current Liabilities | ¥3.53B | ¥3.27B | +¥261M |
| Accounts Payable | ¥440M | ¥413M | +¥27M |
| Short-term Loans | ¥1.07B | ¥680M | +¥395M |
| Non-current Liabilities | ¥1.25B | ¥1.46B | ¥-210M |
| Long-term Loans | ¥1.11B | ¥1.25B | ¥-142M |
| Total Liabilities | ¥4.78B | ¥4.73B | +¥51M |
| Total Equity | ¥4.86B | ¥4.86B | +¥4M |
| Capital Stock | ¥50M | ¥50M | ¥0 |
| Capital Surplus | ¥3.86B | ¥3.86B | ¥-1M |
| Retained Earnings | ¥957M | ¥928M | +¥30M |
| Treasury Stock | ¥-116M | ¥-116M | ¥0 |
| Owners' Equity | ¥4.80B | ¥4.76B | +¥37M |
| Working Capital | ¥3.26B | - | - |